{"id":69834,"date":"2026-07-13T16:01:53","date_gmt":"2026-07-13T08:01:53","guid":{"rendered":"https:\/\/flcube.com\/?p=69834"},"modified":"2026-07-13T16:01:54","modified_gmt":"2026-07-13T08:01:54","slug":"sanofi-secures-fda-approval-for-sarclisa-escena-subcutaneous-formulation-first-dual-administration-anti-cancer-therapy-for-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69834","title":{"rendered":"Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma"},"content":{"rendered":"\n

Sanofi S.A.<\/strong> (NASDAQ: SNY<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved the subcutaneous (SC) formulation Sarclisa (isatuximab-irfc) Escena<\/strong> in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM)<\/strong>, covering all existing indications of the Sarclisa intravenous (IV) formulation.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>U.S. FDA<\/td><\/tr>
Approval Type<\/strong><\/td>New drug formulation approval<\/td><\/tr>
Product<\/strong><\/td>Sarclisa Escena (isatuximab-irfc) subcutaneous formulation<\/td><\/tr>
Indication<\/strong><\/td>Multiple myeloma (all existing IV formulation indications)<\/td><\/tr>
Approval Date<\/strong><\/td>10 Jul 2026<\/td><\/tr>
Key Innovation<\/strong><\/td>First anti-cancer treatment with dual administration options: on-body injector (OBI) and manual SC injection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

This approval represents a significant advancement in multiple myeloma treatment delivery, offering patients and healthcare providers flexible administration options while maintaining therapeutic efficacy.<\/p>\n\n\n\n

Clinical Evidence \u2013 IRAKLIA Phase III Study<\/h2>\n\n\n\n
Endpoint<\/th>Result (Sarclisa Escena vs. IV)<\/th><\/tr><\/thead>
Primary Endpoint<\/strong><\/td>Non-inferiority in efficacy demonstrated<\/td><\/tr>
Pharmacokinetics<\/strong><\/td>Similar exposure profiles between SC and IV formulations<\/td><\/tr>
Safety Profile<\/strong><\/td>Comparable overall safety with reduced infusion-related reactions<\/td><\/tr>
Treatment Time<\/strong><\/td>Significantly shortened compared to IV infusion<\/td><\/tr>
Study Design<\/strong><\/td>Pivotal Phase III non-inferiority trial<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The IRAKLIA study provided robust evidence supporting the transition from IV to SC administration without compromising clinical outcomes, while delivering meaningful improvements in patient convenience and healthcare resource utilization.<\/p>\n\n\n\n

Product Innovation & Administration Options<\/h2>\n\n\n\n